A recent meeting of an FDA advisory committee has asked wants the FDA to limit the duration of bisphosphonate therapy for treatment of osteoporosis, but the committee could not agree on a time limit to recommend. […]
An interesting, but it makes sense type of study, was discussed about the relationship between high levels of triglycerides (TG) and the development of prostate cancer, including more aggresive prostate cancer. It of course follows suite that prostate cancer diagnosed with higher gleason scores (more aggressive) leads to more advanced prostate cancer. This study which [...]
The question of today’s post is do men with advanced prostate cancer develop treatment regrets concurrent to their development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation)? To answer this question researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry [...]
New data, published September 1 in the Journal of Urology, shows that Firmagon® (degarelix) which is a gonadotropin-releasing hormone therapy (GnRH) given to men with advanced prostate cancer may be superior to leuprolide when used over three years. This new study (CS21A) was an open-label extension of the Phase III study (CS21) in which Firmagon® [...]
Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]